Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.85 |
| ▸ | JAK3 | P52333 | 20/20 | 0.85 |
| ▸ | JAK2 | O60674 | 12/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | TYK2 | P29597 | 1/20 | 0.76 |
| ▸ | SYK | P43405 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340213 | 0.99 | JAK1 (0.84) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL341375 | 0.96 | JAK1 (0.82) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL525129 | 0.95 | JAK1 (0.79) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL340449 | 0.94 | JAK1 (0.77) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL15389273 | 0.94 | JAK1 (0.77) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29610607 | 0.94 | JAK1 (0.77) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL340833 | 0.94 | JAK1 (0.77) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29921229 | 0.94 | JAK1 (0.76) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL342259 | 0.94 | JAK1 (0.76) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL341220 | 0.94 | JAK1 (0.85) | JAK1JAK3JAK2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218705-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | US | claimed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | claimed |
| US-11220496-B2 | Compounds and method for treating autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-11 | — | — | US | claimed |
| US-20210198248-A1 | FUMARATE SALT OF 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[D]OXAZOL-2(3H)-ONE | MIDCAP FINANCIAL TRUST | 2021-07-01 | — | — | US | claimed |
| EP-3823964-A1 | A XINAFOATE SALT OF A JAK INHIBITING COMPOUND | Astrazeneca AB (SE) | 2021-05-26 | — | — | EP | claimed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | claimed |
| EP-3802523-A1 | FUMARATE SALT OF 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[D]OXAZOL-2(3H)-ONE | Astrazeneca AB (SE) | 2021-04-14 | — | — | EP | claimed |
| CN-112424187-A | Xinafoate salts of JAK-inhibiting compounds | 阿斯利康(瑞典)有限公司 | 2021-02-26 | — | — | CN | claimed |
| WO-2021026451-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | WO | claimed |
| CN-112154148-A | Fumarate salt of 5- ((5-methyl-2- ((3,4, 5-trimethylphenyl) amino) pyrimidin-4-yl) amino) -benzo [ d ] oxazol-2 (3H) -one | 阿斯利康(瑞典)有限公司 | 2020-12-29 | — | — | CN | claimed |
| EP-2598500-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | claimed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | claimed |
| EP-2565193-A1 | Compositions and methods for inhibition of the JAK pathway | Rigel Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | claimed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | claimed |
| EP-2389372-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | claimed |
| US-8037782-B2 | Steering column assembly | FUJI KIKO CO., LTD. (JP) | 2011-10-18 | — | — | US | claimed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220496-B2 | Compounds and method for treating autoimmune diseases | NR1H2, CNR2, CNR1 | JAK1 2860/4885JAK3 2785/4885JAK2 1240/4885 |
| US-20120016122-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20220218705-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | NR1H2, CNR2, CNR1 | JAK1 2860/4885JAK3 2785/4885JAK2 1240/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20210198248-A1 | FUMARATE SALT OF 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[D]OXAZOL-2(3H)-ONE | JAK1, JAK2, STAT5A | JAK1 1/4885JAK3 4/4885JAK2 2/4885 |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.